Friday, September 01, 2023
Ono Pharmaceutical has entered into a significant drug discovery collaboration agreement with Twist Bioscience, marking a crucial step in their efforts to develop groundbreaking antibody-based therapies for autoimmune diseases.
In this collaboration, Twist Bioscience will utilise its extensive Twist Biopharma Solutions Library of Libraries to conduct research focused on discovering innovative antibodies tailored to therapeutic areas identified by Ono. This library comprises artificially synthesised antibody collections based on natural sequences, known for their advanced structural and developability features, offering a strong foundation for targeting a wide range of drug targets efficiently.
With this agreement, Ono Pharmaceutical secures exclusive global rights for the development, manufacturing, and commercialisation of therapeutic antibody drugs arising from the collaboration. Ono will support the research and development efforts by paying research fees, offering milestone payments tied to clinical and regulatory achievements, and providing tiered royalties based on global net sales.
This collaboration signifies a significant boost to the field of biologics drug discovery, with a shared mission to expedite the development of innovative medications for individuals suffering from autoimmune diseases.
By combining Twist Bioscience's expertise in antibody discovery with Ono's extensive experience in drug development, the partnership holds great promise in paving the way for potential breakthrough treatments in the realm of autoimmune diseases, offering hope for patients seeking effective therapies.
